Safety and Immunogenicity of DAPTACEL Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With DAPTACEL or Pentacel.

Trial Profile

Safety and Immunogenicity of DAPTACEL Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With DAPTACEL or Pentacel.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2014

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 11 May 2010 Actual patient numbers changed from 650 to 649 as reported by ClinicalTrials.gov.
    • 24 Sep 2008 Primary endpoint identified as to provide information concerning the safety of DTaP vaccine as reported by ClinicalTrials.gov
    • 24 Sep 2008 Actual patient number (650) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top